IL-28B基因多态性对慢性丙型肝炎1型患者基于蛋白酶抑制剂的三联疗法的预测性：一项荟萃分析。

Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis.

作者信息

Mechie Nicolae-Catalin, Röver Christian, Cameron Silke, Amanzada Ahmad

机构信息

Nicolae-Catalin Mechie, Silke Cameron, Ahmad Amanzada, Department of Gastroenterology and Endocrinology, University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, Germany.

出版信息

World J Hepatol. 2014 Oct 27;6(10):759-65. doi: 10.4254/wjh.v6.i10.759.

DOI:10.4254/wjh.v6.i10.759

PMID:25349647

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4209421/

Abstract

AIM

To investigate the predictability of interleukin-28B single nucleotide polymorphism rs12979860 with respect to sustained virological response (SVR) in chronically hepatitis C virus (HCV) genotype-1 patients treated with a protease-inhibitor and pegylated interferon-α (Peg-INF-α) based triple-therapy.

METHODS

We searched PubMed, the Cochrane Library and Web of Knowledge for studies regarding the interleukin 28B (IL-28B)-genotype and protease-inhibitor based triple-therapy. Ten studies with 2707 patients were included into this meta-analysis. We used regression methods in order to investigate determinants of SVR.

RESULTS

IL-28B-CC-genotype patients achieved higher SVR rates (odds 5.34, 95%CI: 3.81-7.49) than IL-28B-non-CC-genotype patients (1.88, 95%CI: 1.43-2.48) receiving triple-therapy. The line of therapy (treatment-naïve or -experienced for Peg-INF-α) did not affect the predictive value of IL-28B (P = 0.1). IL-28B-CC-genotype patients treated with protease inhibitor-based triple-therapy consisting of Boceprevir, Simeprevir, Telaprevir or Vaniprevir showed odds of 3.38, 14.66, 7.84 and 2.91, respectively. The odds for CC genotype patients treated with Faldaprevir cannot be quantified, as only a single study with a 100% SVR rate was available.

CONCLUSION

IL-28B-SNP predicts the outcome for chronic HCV genotype-1 patients receiving protease inhibitor-based triple-therapy. The predictive value varies between the different protease inhibitors.

摘要

目的

探讨白细胞介素-28B单核苷酸多态性rs12979860对接受蛋白酶抑制剂和聚乙二醇化干扰素-α（Peg-INF-α）三联疗法治疗的慢性丙型肝炎病毒（HCV）1型患者持续病毒学应答（SVR）的预测性。

方法

我们在PubMed、Cochrane图书馆和知识网络中检索了有关白细胞介素28B（IL-28B）基因型和基于蛋白酶抑制剂的三联疗法的研究。本荟萃分析纳入了10项研究中的2707例患者。我们采用回归方法来研究SVR的决定因素。

结果

接受三联疗法的IL-28B-CC基因型患者的SVR率（优势比5.34，95%置信区间：3.81-7.49）高于IL-28B非CC基因型患者（1.88，95%置信区间：1.43-2.48）。治疗方案（初治或接受过Peg-INF-α治疗）不影响IL-28B的预测价值（P = 0.1）。接受基于蛋白酶抑制剂的三联疗法（包括博赛匹韦、simeprevir、特拉匹韦或万尼普韦）治疗的IL-28B-CC基因型患者的优势比分别为3.38、14.66、7.84和2.91。由于仅有一项SVR率为100%的研究，因此无法量化接受faldaprevir治疗的CC基因型患者的优势比。